MedTrace Logo

Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South Africa

NCT04205721 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23061

Last updated 2019-12-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the impact of the new South African Department of Basic Education (DBE) sexuality and HIV education program that uses scripted lesson plans and supporting activities and will be implemented by Education Development Center (EDC). The primary outcomes are the incidence of HSV-2 or pregnancy among a cohort of learners in grade 8 and followed for two years in two provinces of South Africa.

Conditions

  • HSV-2 Infection
  • HIV Infections
  • Pregnancy Related

Interventions

BEHAVIORAL

School-based sexuality and HIV prevention scripted lesson plans

The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.

Sponsors & Collaborators

  • University of Pretoria

    collaborator OTHER

  • SADC Research Centre

    collaborator UNKNOWN

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Ilene Speizer, PhD · University of North Carolina, Chapel Hill

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-08
Primary Completion
2018-11-04
Completion
2018-11-15

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04205721 on ClinicalTrials.gov